Novartis' Galvus NDA Follows Close On The Heels Of Merck's Januvia
The likely late November user fee date for Novartis' DPP-IV inhibitor vildagliptin is mere weeks behind that for sitagliptin.
The likely late November user fee date for Novartis' DPP-IV inhibitor vildagliptin is mere weeks behind that for sitagliptin.